Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Stock Information for Alterity Therapeutics Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Alterity Therapeutics Limited

Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy
Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy
Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.